1
Return

Reply to Yılmaz et al., “Caution in Interpreting Tralokinumab Outcomes in Dupilumab Nonresponders”

delete2026-08-06
delete0
PRE
AI
V
Vikash Oza
T
Theodora K. Karagounis *
DOI:10.1016/j.jaad.2026.07.120delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En

Journal

Journal of the American Academy of Dermatology cover
Journal of the American Academy of Dermatology
IF:
11.8
Papers:
2.6W
Citations:
3.9W

Organization

N
new york university
Scholars:
5.4K
Papers: 2.6K
Citations: 1
Cited Papers

Cited Papers

Citing Papers

Citing Papers